Szekeres David Leslie
Known title: EVP, Chief Operating OfficerCIK: 0001602459
Associated companies
Transaction History
| HRTX | ▲ Buy | Option Exercise | 1,250 | — | 7/13/2023 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 4,564 | — | 7/13/2023 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 2,012 | $3K | 7/13/2023 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 1,250 | — | 4/13/2023 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 4,564 | — | 4/13/2023 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 2,012 | $6K | 4/13/2023 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 4,564 | — | 1/13/2023 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 2,012 | $6K | 1/13/2023 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 1,250 | — | 1/13/2023 | View on chart |
| HRTX | ▼ Sell | Other | 1,654 | $5K | 10/31/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 1,250 | — | 10/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 4,564 | — | 10/13/2022 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 2,012 | $8K | 10/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 4,564 | — | 7/13/2022 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 2,012 | $6K | 7/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 1,250 | — | 7/13/2022 | View on chart |
| HRTX | ▼ Sell | Other | 1,505 | $6K | 4/29/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 1,250 | — | 4/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 4,564 | — | 4/13/2022 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 2,012 | $12K | 4/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 1,250 | — | 1/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 4,564 | — | 1/13/2022 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 2,012 | $17K | 1/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 1,250 | — | 10/13/2021 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 433 | $5K | 10/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Heron Therapeutics Signs U.S. License Deal
Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.
Heron Therapeutics Signs U.S. License Deal. Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.